Fintel reports that on March 14, 2025, Cantor Fitzgerald initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a ...

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from ...

Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs ...

Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline ...

A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time ...

Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline ...

Choline is a crucial nutrient that performs important roles in the human body. It is necessary for the functioning of cell membranes, neurotransmitters, and liver. While choline can be found in ...

Metabolic related diseases such as cancer, diabetes mellitus and atherosclerosis are major challenges for human health and safety worldwide due to their associations with high morbidity and mortality.